Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

, MRK

Merck

$62.77

0.11 (0.18%)

07:55
10/10/16
10/10
07:55
10/10/16
07:55

Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data

Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.

BMY

Bristol-Myers

$55.43

0.38 (0.69%)

MRK

Merck

$62.77

0.11 (0.18%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$55.43

0.38 (0.69%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

RGA

Reinsurance Group

$126.86

-0.36 (-0.28%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Reinsurance Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

SRCL

Stericycle

$77.24

-1.01 (-1.29%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Stericycle management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 03

    Aug

THO

Thor Industries

$107.33

-1.47 (-1.35%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Thor Industries management to meet with Cancaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 06

    Jul

IDCC

InterDigital

$79.80

-0.65 (-0.81%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
InterDigital management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

NP

Neenah Paper

$77.80

-1.6 (-2.02%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Neenah Paper management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

AGCO

AGCO

$66.47

-0.67 (-1.00%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
AGCO management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 10

    Aug

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
Pending Home Sales Index to be reported at 10:00 »

May Pending Home Sales…

PRTS

U.S. Auto Parts

$3.23

-0.02 (-0.62%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
U.S. Auto Parts management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
JPMorgan life sciences analyst holds an analyst/industry conference call »

Life Science Tools &…

STE

STERIS

$81.47

-1.64 (-1.97%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
STERIS management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

VTR

Ventas

$71.17

-0.76 (-1.06%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Ventas management to meet with Raymond James »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

SMTC

Semtech

$34.85

-0.6 (-1.69%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Semtech management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

IVZ

Invesco

$34.77

-0.24 (-0.69%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Invesco management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

DHXM

DHX Media

$4.30

0.15 (3.61%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
DHX Media management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

May International Trade…

PODD

Insulet

$49.00

-1.22 (-2.43%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Insulet participates in a conference call with Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

NFG

National Fuel

$55.85

-0.45 (-0.80%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
National Fuel management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

OXY

Occidental Petroleum

$59.63

-0.38 (-0.63%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Occidental Petroleum management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

04:55
06/28/17
06/28
04:55
06/28/17
04:55
General news
Breaking General news story  »

Week of 6/23 EIA…

NBIX

Neurocrine

$45.56

-1.75 (-3.70%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 29

    Jun

LPI

Laredo Petroleum

$10.03

0.24 (2.45%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Laredo Petroleum management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MPWR

Monolithic Power

$96.84

-2.67 (-2.68%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Monolithic Power management to meet with Oppeneimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

TRS

TriMas

$20.60

-0.1 (-0.48%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
TriMas management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ORCL

Oracle

$50.75

-0.11 (-0.22%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
Oracle management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UNFI

United Natural Foods

$34.95

-0.08 (-0.23%)

04:55
06/28/17
06/28
04:55
06/28/17
04:55
Conference/Events
United Natural Foods management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 13

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.